Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act 1934
Date of
Report (date of earliest event reported): October 16, 2009
JIANGBO
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in charter)
Florida
(State or
other jurisdiction of incorporation)
|
333-86347
|
65-1130026
|
|
(Commission File
Number)
|
(IRS Employer Identification
No.) |
|
Middle
Section, Longmao Street, Area A, Laiyang Waixiangxing Industrial
Park
|
|
Laiyang
City, Yantai, Shandong Province, People’s Republic of China
26520
|
(Address
of principal executive offices and zip code)
(0086)535-7282997
(Registrant's
telephone number including area code)
(Registrant's
former name or former address, if changed since last report)
GENESIS PHARMACEUTICALS ENTERPRISES,
INC.
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR
240.14a-12(b))
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02 Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On
October 22, 2009, Jiangbo Pharmaceuticals, Inc. (the “Company”) issued a press
release announcing that on October 16, 2009, the Company received a letter from
Mr. Xu Haibo stating that he shall resign from his position as the
Company’s Chief Operating Officer, effective as of October 20, 2009, due to
health reasons. Mr. Xu, however, shall remain a member of the
Company’s Board of Directors. There were no disagreements between Mr.
Xu and the Company on any matter relating to the Company’s operations, policies
or practices, which resulted in his resignation as Chief Operating
Officer. A copy of Mr. Xu’s resignation letter is attached hereto as
Exhibit 99.1. A copy of the press release is also attached hereto as Exhibit
99.2.
Item
9.01 Financial Statements
and Exhibits.
|
Exhibit No.
|
Description
|
| |
|
|
99.1
|
Resignation
Letter of Mr. Xu Haibo dated October 16, 2009.
|
| |
|
|
99.2
|
Press
Release dated October 22,
2009.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
JIANGBO
PHARMACEUTICALS, INC. |
|
| |
|
|
|
|
|
By:
|
/s/ Cao
Wubo |
|
| |
Name:
|
Cao
Wubo |
|
| |
Title: |
Chief
Executive Officer |
|
| |
|
|
|
Dated:
October 22, 2009